An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of ...

A new study found that low or absent disease activity, hydroxychloroquine (HCQ) use, and gradual reduction of GC dosing can ...

The Phase 1 GALLOP study evaluating the investigational therapy, CB-010, for treatment of lupus nephritis has launched.

Exagen Inc. has announced conditional approval from the New York State Department of Health for its innovative new biomarker ...

A new study investigates the role of Krüppel-like factor 2 (KLF2, a protein coding gene involved in a variety of regulatory ...

Lupus affects different people in different ways, and skin problems like rashes or sores re common. In a new study, people ...

IGM Biosciences announced the discontinuation of imvotamab and IGM-2644 for autoimmune and inflammatory diseases, including lupus.

In a new study published in Lupus Science & Medicine, researchers reviewed randomized clinical trials (RCTs) to assess therapies for initial management of lupus nephritis (LN), focusing on their ...

In the Phase 2b CARE study, the investigational drug, cenerimod, demonstrated safe and effective results for treatment of ...

The Patient-Physician Dialogue Tool (PDF) is a guide to support people going through the process of diagnosis. It includes a checklist and some pointers on questions to ask to make the most of your ...

There is no easy way to describe Nick Cannon, 32. To say he is a man of multiple talents is an understatement. He’s a successful actor, radio and television personality, comedian, songwriter-rapper, ...

Lupus is a chronic (long-term) disease that can cause inflammation (swelling) and pain in any part of your body. It’s an autoimmune disease, meaning that your immune system attacks healthy tissue ...